First study in the world to define blood based biomarkers 90% accurate to detect AD pathology in a group of mixed individuals over the age of 60

The Challenge: There is no knows cure for Alzheimer’s Disease

The challenge is to define a set of biomarkers that are associated with the early identification of AD.

By identifying biomarkers for the early identification of AD, we can help in the selection of participants for clinical trials, reducing their cost, and increasing their benefit.

The Response: 

Assess fluid based biomarkers that are associated with disease pathology as measured via PET imaging.

The Results: Bridging the communication gaps between clinicians and patients

Defined the disease trajectory over time with collaborators in Melbourne.  Defined blood based biomarkers that are 90% accurate to disease amyloid pathology. The first study in the world to define blood based biomarkers 90% accurate to detect AD pathology in a group of mixed individuals over the age of 60.

aibl – the Australian Imaging, Biomarkers & Lifestyle Flagship Study of Ageing.

.